What were the key takeaways from Atossa Therapeutics’s earnings call?

What guidance did Atossa Therapeutics's management provide for the next earnings period?

What factors drove the changes in Atossa Therapeutics's revenue and profit?

What is Atossa Therapeutics's latest dividend and current dividend yield?

Did Atossa Therapeutics beat or miss consensus estimates last quarter?

What does Atossa Therapeutics do and what are its main business segments?

What is the revenue and EPS growth rate for Atossa Therapeutics year over year?

What is the market's earnings forecast for Atossa Therapeutics next quarter?

- **Z-endoxifen Showcases Promising Efficacy**: 85% of premenopausal patients achieved <10% Ki-67 at 4 weeks, with no severe toxicities. Metastatic trial data shows 26% clinical benefit in refractory patients and 5-month PFS improvement vs. tamoxifen.
- **Financial Discipline Maintained**: 12% YoY operating expense reduction to $27.6M, supported by $3.2M R&D savings and strong $71.1M cash balance.
- **Strategic Focus on U.S. FDA Approval**: 2025 dedicated to securing metastatic indication; global expansion planned post-U.S. regulatory approval.

**【CEO Business Update】**
- **Z-endoxifen Clinical Progress**: Advanced Phase II EVANGELINE trial in premenopausal women shows 4-week Ki-67 reduction below 10% in 85% of patients, with no significant Grade 3/4 toxicities. A 40mg dose regimen is being evaluated alongside exemestane for metastatic breast cancer.
- **Metastatic Breast Cancer Focus**: Prioritizing metastatic indication to expedite FDA approval, with plans to engage KOLs and the FDA over the next 4-6 months. Phase II trial data highlights 26% clinical benefit rate in endocrine-refractory patients and 5-month PFS improvement vs. tamoxifen in CDK4/6 inhibitor-naïve subgroups.
- **Global Expansion Strategy**: 2025 focused on U.S. FDA approval; international markets (e.g., Europe, Australia) will follow post-U.S. regulatory clarity.

**【CFO Financial Highlights】**
- **2024 Operating Expenses**: Total $27.6M (down 12% YoY), driven by $3.2M R&D savings (clinical trial reductions) and $500K G&A cost cuts.
- **Cash Position**: $71.1M at year-end, providing runway for Z-endoxifen trials and research initiatives.
- **Key Expense Breakdown**: 
  - R&D: $14.1M (vs. $17.3M YoY), including $2.6M clinical trial savings.
  - G&A: $13.5M (vs. $14.0M YoY), with $1.9M lower compensation costs offset by $1.8M higher legal/public company fees.
  - Interest Income: $4.1M (stable YoY).

Atossa Therapeutics (ATOS)-25 Mar 25-2024 Q4 Earnings call transcript

Atossa Therapeutics (ATOS)-14 Aug 23-2023 Q2 Earnings call transcript

Atossa Therapeutics (ATOS)-27 Jul 22-2022 Q2 Earnings call transcript

Actual								-4.8	-6.45	-5.1	-13.2	-0.6	-0.9	-0.6	-0.6	-0.6	-0.75	-0.9	-0.9	-0.75	-1.2	-0.75	-0.9	-0.75	-0.75	-0.9	-0.6	-0.75	-1.05
Forecast								-5.85	-4.2	-5.175	-3.75	-0.75	-0.525	-0.825	-0.675	-0.75	-0.75	-0.825	-0.975	-0.9	-0.9	-1	-0.9	-1	-0.9	-0.9	-0.95	-0.85	-0.8625
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+17.95%	-53.57%	+1.45%	-252.00%	+20.00%	-71.43%	+27.27%	+11.11%	+20.00%	0.00%	-9.09%	+7.69%	+16.67%	-33.33%	+25.00%	0.00%	+25.00%	+16.67%	0.00%	+36.84%	+11.76%	-21.74%

Actual	--	--	--	--	--	--	--	--	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Forecast	--	--	--	--	--	--	--	--	--	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

ATOS

ATOS fundamentals

ATOS Q2 2025 Earnings

Earnings Call

You can ask Aime

ATOS

ATOS fundamentals

ATOS Q2 2025 Earnings

Earnings Call

ATOS Earnings Call Summary for Q2/2025 Mar 26, 2026

ATOS Earnings Call Summary for Q1/202512:30 PM on May 13, 2025

ATOS Earnings Call Summary for Q4/20248:30 AM on Mar 25, 2025

ATOS Earnings Call Summary for Q3/2024 Mar 26, 2026

ATOS Earnings Call Summary for Q2/2024 Mar 26, 2026

You can ask Aime